Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
106.73
+0.97 (0.92%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Neurocrine Biosciences Stock Forecast

Stock Price Forecast

The 20 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 162.3, with a low estimate of 114 and a high estimate of 219. The average target predicts an increase of 52.07% from the current stock price of 106.73.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $114 $162.3 $163 $219
Change +6.81% +52.07% +52.72% +105.19%

Analyst Ratings

The average analyst rating for Neurocrine Biosciences stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Nov '24Dec '24Jan '25Feb '25Mar '25Apr '25
Strong Buy 865667
Buy 111111111111
Hold 555442
Sell 000000
Strong Sell 000000
Total 242221212120

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Evercore ISI Group
Evercore ISI Group
Buy
Maintains
$190$185
Buy Maintains $190$185 +73.33% Apr 24, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$185$168
Strong Buy Maintains $185$168 +57.41% Apr 22, 2025
Needham
Needham
Strong Buy
Upgrades
$138
Strong Buy Upgrades $138 +29.30% Apr 15, 2025
RBC Capital
RBC Capital
Buy
Upgrades
$138$137
Buy Upgrades $138$137 +28.36% Apr 14, 2025
UBS
UBS
Strong Buy
Maintains
$154$137
Strong Buy Maintains $154$137 +28.36% Apr 4, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
2.72B
from 2.36B
Increased by 15.36%
Revenue Next Year
3.16B
from 2.72B
Increased by 16.34%
EPS This Year
4.19
from 3.29
Increased by 27.36%
EPS Next Year
6.45
from 4.19
Increased by 54.01%
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
1.05B1.13B1.49B1.89B2.36B2.72B3.16B3.61B
Revenue Growth
32.71%8.38%31.34%26.76%24.81%15.36%16.34%14.33%
EPS
4.160.921.562.473.294.196.459.16
EPS Growth
966.67%-77.89%69.57%58.33%33.20%27.36%54.01%42.02%
Forward PE
-----25.4716.5411.65
No. Analysts
-----272320
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20252026202720282029
High 2.9B 3.5B 4.4B
Avg 2.7B 3.2B 3.6B
Low 2.5B 2.8B 3.1B

Revenue Growth

Revenue Growth 20252026202720282029
High
22.9%
30.6%
38.6%
Avg
15.4%
16.3%
14.3%
Low
7.0%
2.3%
-1.1%

EPS Forecast

EPS 20252026202720282029
High 6.46 9.64 14.84
Avg 4.19 6.45 9.16
Low 2.49 3.60 3.08

EPS Growth

EPS Growth 20252026202720282029
High
96.3%
130.0%
129.9%
Avg
27.4%
54.0%
42.0%
Low
-24.3%
-14.2%
-52.3%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.